Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Challenge Study of rDEN2delta30-7169 in Dengue Virus Infection
NCT07706686Phase 1Recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Aug 2026
- Primary completion
- Nov 2028
- Countries
- 1
01
Overview
Phase 1, open-label trial of rDEN2Δ30-7169 in dengue fever (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Adverse Events and Serious Adverse Events at Day 180, Peak Viral RNAemia Titers and 1 more. Started Aug 2026; status: recruiting.
02
Drugs
rDEN2Δ30-7169
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT07706686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07706686.